- Home
- TPC vs RARE Comparison
TPC vs RARE Comparison
Compare TPC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPC
- RARE
- Stock Information
- Founded
- TPC 1894
- RARE 2010
- Country
- TPC United States
- RARE United States
- Employees
- TPC N/A
- RARE N/A
- Industry
- TPC General Bldg Contractors - Nonresidential Bldgs
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- TPC Consumer Discretionary
- RARE Health Care
- Exchange
- TPC Nasdaq
- RARE Nasdaq
- Market Cap
- TPC 2.5B
- RARE 2.6B
- IPO Year
- TPC N/A
- RARE 2014
- Fundamental
- Price
- TPC $62.62
- RARE $31.82
- Analyst Decision
- TPC Strong Buy
- RARE Strong Buy
- Analyst Count
- TPC 3
- RARE 14
- Target Price
- TPC $60.67
- RARE $86.64
- AVG Volume (30 Days)
- TPC 633.0K
- RARE 1.3M
- Earning Date
- TPC 11-05-2025
- RARE 11-04-2025
- Dividend Yield
- TPC N/A
- RARE N/A
- EPS Growth
- TPC N/A
- RARE N/A
- EPS
- TPC N/A
- RARE N/A
- Revenue
- TPC $4,770,779,000.00
- RARE $610,159,000.00
- Revenue This Year
- TPC $23.30
- RARE $19.72
- Revenue Next Year
- TPC $12.61
- RARE $23.29
- P/E Ratio
- TPC N/A
- RARE N/A
- Revenue Growth
- TPC 12.03
- RARE 26.77
- 52 Week Low
- TPC $18.34
- RARE $25.81
- 52 Week High
- TPC $63.96
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- TPC 75.33
- RARE 61.88
- Support Level
- TPC $56.62
- RARE $31.03
- Resistance Level
- TPC $60.41
- RARE $32.58
- Average True Range (ATR)
- TPC 1.82
- RARE 0.88
- MACD
- TPC 0.05
- RARE 0.38
- Stochastic Oscillator
- TPC 99.72
- RARE 79.62
About TPC Tutor Perini Corporation
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.